Human medicines European public assessment report (EPAR): Itvisma, onasemnogene abeparvovec, Date of authorisation: 30/06/2026, Status: Authorised
RegulatoryapprovedItvismaPositive
AI Analysis
Summary
Itvisma (onasemnogene abeparvovec) received European Union authorization on June 30, 2026. The medicine is now approved for use in the EU.
Outcome Details
European Union authorization granted
Importance:8/10
Sentiment:
1.00
EMA approvalGene therapyEuropean authorization
Related Companies
Read the original article
Published by EMA New Human Medicines on July 28, 2026 4:00 PM